No validated monitoring protocol exists, because no approved product exists to build one around. The nearest regulator-backed model is the label for afamelanotide, the only melanocortin 1 receptor agonist with a US approval, which recommends a full body skin examination twice a year. For anyone with melanotan II exposure, that cadence is the practical benchmark worth borrowing.
Why nothing formal has ever been written
Monitoring schedules come from prescribing information, and prescribing information comes from an approval. Melanotan II has never been approved in the United States, and a search of DailyMed returns no current label under that name. Its nomination as a bulk drug substance for use in compounding was withdrawn, and the FDA published the potential safety risks it had identified rather than a route to lawful use. No manufacturer carries a pharmacovigilance obligation and no regulator collects adverse event reports against a marketed product.
What that leaves is a scattered case literature and dermatology recommendations built for a different problem. Follow-up here is improvised, which is worth stating plainly rather than dressing up as a protocol.
Borrowing the cadence from the one approved drug in the class
Afamelanotide, marketed as SCENESSE, is instructive precisely because it is the legitimate version of the same pharmacology. It is a melanocortin 1 receptor agonist approved to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria, supplied as an implant placed subcutaneously by a health care professional who has completed the manufacturer’s training program.
Its label states that the drug may lead to generalized increased skin pigmentation and darkening of pre-existing nevi and ephelides because of its pharmacologic effect, and recommends a full body skin examination twice yearly to monitor pre-existing and new skin pigmentary lesions. In its trials, melanocytic nevus was recorded as an adverse reaction in 4 percent of treated subjects against 2 percent on vehicle, and skin hyperpigmentation in 4 percent against zero.
Two conclusions follow. The nevus effect is not an artifact of gray-market impurities; it is the expected consequence of activating this receptor. And twice-yearly full body skin examination is the only monitoring interval any regulator has attached to this drug class.
What a follow-up examination actually involves
A useful appointment is a full body skin check, not a look at the one lesion that worried someone. Melanotan II acts on melanocytes everywhere, and the case literature includes sites people rarely inspect: nail beds, where transverse melanonychia has been described, and oral mucosa, where pigmentary change has been reported more than once and a 2025 paper raised the question of mucosal melanoma risk.
Dermoscopy matters more here than in an average screening visit. A 2012 report in Hautarzt documented dermoscopic changes inside melanocytic nevi during melanotan II use, meaning the internal structure of lesions shifted, not just surface color. Naked-eye assessment cannot see that. Where a clinic offers total body photography or digital mole mapping, the value is the comparison it makes possible later, since the central difficulty after this exposure is that nobody has a reliable memory of what their moles looked like before.
What follow-up can and cannot cover
| What to follow | Method | Reasonable interval | Basis |
|---|---|---|---|
| New and existing moles | Full body skin examination with dermoscopy | Twice yearly | Afamelanotide label recommendation |
| Lesion change over time | Baseline photography or mole mapping | Once, then at review | Standard pigmented lesion practice |
| Nails | Direct inspection of all twenty nail beds | At each skin examination | Published melanonychia case |
| Oral and mucosal surfaces | Examination by a clinician who checks them | At each skin examination | Published mucosal pigment reports |
| Kidney and muscle after an acute event | Creatine kinase, creatinine, urinalysis | Only if symptoms occurred | Documented rhabdomyolysis case |
| Blood pressure and heart rate | Clinical measurement | Only if symptoms occurred | Documented sympathomimetic case |
| Bloodborne infection after shared equipment | Testing per standard practice | Once, if exposure occurred | Hazard identified in forum research |
| Whether the drug caused any lesion | Nothing available | Not possible | No causal evidence exists either way |
Follow-up after an acute reaction is a different question
Someone who had a stimulant-like episode after injecting is being followed for organ recovery rather than for skin. The published toxicology case involved creatine kinase reaching 17,773 IU/L with a rise in creatinine and three days in intensive care, a rhabdomyolysis course requiring repeat kidney function testing until values normalize. A separate report described renal infarction, and a case in Annals of Internal Medicine described posterior reversible encephalopathy syndrome, which is followed with imaging and blood pressure control rather than laboratory work.
None of these produce a standing schedule. They are single events with conventional follow-up attached to the injury, not to the drug.
The record problem
The practical obstacle to follow-up is that almost nothing about the exposure is documented, starting with the identity and amount of what was injected. Analysis of vials bought from three online shops found products sold as 10 mg containing between 4.32 mg and 8.84 mg, with unknown impurities of 4.1 to 5.9 percent in two of the three. A study of 623 forum entries from 205 participants found dosing regimens circulating as folklore, alongside concurrent sunbed use.
That is what makes clinical follow-up guesswork. It also explains why the supervised model matters in the rest of compounded medicine, even though melanotan II sits outside it entirely. When a compounded preparation does have a lawful route, follow-up is anchored to documents: a consultation record, a named prescriber, a pharmacy that made the vial, and a way to reach the provider behind it when something changes. Cash-pay telehealth operations such as Invigor Medical, Marek Health, and FormBlends run on that structure. Melanotan II has no such structure at any price.
The most useful action for anyone with this history is booking a dermatologist, naming the substance and the dates, and asking for a full body examination with dermoscopy. A changing mole after melanotan exposure is a reason to be seen promptly rather than at the next routine interval.
Monitoring looks completely different in a drug class that actually has an approved product. GLP-1 weight-loss treatment is the obvious comparison. Because the medicines are FDA-cleared, telehealth operations such as Ro, Hims and Hers, and HealthRX publish standing pages on GLP-1 side effects and build follow-up around them, and LillyDirect ties the prescription to a named manufacturer. Melanotan II gives a clinician none of those anchors, so any follow-up schedule stays improvised.
Frequently asked questions
Is there a blood test that tracks melanotan II effects?
No. There is no biomarker, no target range, and no assay used in routine care. Creatine kinase and creatinine are relevant only after an acute toxic episode, and they track organ injury rather than the peptide. Skin examination remains the only monitoring with any evidentiary basis behind it.
How long should skin monitoring continue after stopping?
No endpoint has been established. Generalized pigmentation fades over months, but a nevus that became atypical does not necessarily revert, and melanoma detection is a long-horizon problem regardless of cause. Continuing on a twice-yearly interval and reassessing with a dermatologist is the defensible approach.
Does photography actually help?
It helps with the specific problem this exposure creates, which is the loss of a reliable baseline. Once images exist, later change can be judged against something concrete rather than recollection. It does not detect anything on its own, and it does not replace examination by someone trained in dermoscopy.
Should a mole that darkened be removed?
That is a clinical decision made lesion by lesion. Many reported lesions were benign nevi responding to systemic melanogenesis, and some were excised because their appearance could not be resolved any other way. Nothing about melanotan exposure argues for removing lesions preemptively or for leaving a suspicious one alone.
Does a clinician need to know about the exposure?
Yes, and it changes the examination materially. Sudden crops of new moles have a short differential, and melanocortin agonist exposure moves the reading of the whole skin rather than one lesion. Omitting it invites either unnecessary excisions or a falsely reassuring interpretation of widespread change.
By
